Clinical Trial Update: Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of bicalutamide and ridaforolimus for prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Casodex (bicalutamide) (bicalutamide)
• Ridaforolimus (ridaforolimus)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED